Advertisement

Drugs in R & D

, Volume 8, Issue 4, pp 259–265 | Cite as

Vernakalant

RSD 1235, RSD-1235, RSD1235
Adis R&D Profile

Keywords

Atrial Fibrillation Atrial Flutter Atrial Fibrillation Patient Atrial Arrhythmia Atrial Fibrillation Duration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Technology Vision Group LLC. BioPartnering North America. 4th Annual BioPartnering North America: 5 Feb 2006Google Scholar
  2. 2.
    Cardiome Pharma Corp, Fujisawa Healthcare Inc. Cardiome and Fujisawa sign US$68 million partnership agreement. Media Release: 16 Oct 2003. Available from URL: http://www.cardiome.com Google Scholar
  3. 3.
    Cardiome Pharma Corp. Cardiome And Astellas Amend Agreement. Media Release: 10 Jul 2006. Available from URL: http://www.cardiome.com Google Scholar
  4. 4.
    Cardiome Pharma Corp. Cardiome receives US$6 million milestone payment. Media Release: 23 Feb 2005. Available from URL: http://www.cardiome.com Google Scholar
  5. 5.
    Cardiome Pharma Corporation. Cardiome Reported RSD1235 to Proceed to Phase III Clinical Development. Media Release: 13 May 2003. Available from URL: http://www.cardiome.com Google Scholar
  6. 6.
    Cardiome Pharma Corp, Fujisawa Healthcare Inc. Cardiome’s pivotal AF study achieves primary endpoint. Media Release: 20 Dec 2004. Available from URL: http://www.cardiome.com Google Scholar
  7. 7.
    Cardiome Pharma Corp.. Cardiome completes ACT 1 enrolment. Media Release: 12 Oct 2004. Available from URL: http://www.cardiome.com Google Scholar
  8. 8.
    Cardiome Pharma Corporation. Cardiome initiates cardiac surgery clinical study, revises Phase 3 guidance. Media Release: 29 Mar 2004. Available from URL: http://www.cardiome.com Google Scholar
  9. 9.
    Cardiome Pharma Corp.. Cardiome Reports Additional Phase 1 Trial Data For Oral RSD1235. Media Release: 5 May 2006. Available from URL: http://www.cardiome.com Google Scholar
  10. 10.
    Cardiome Pharma Corporation. Third phase 3 study initiated for Cardiome’s atrial arrhythmia product. Media Release: 7 Jul 2004. Available from URL: http://www.cardiome.com Google Scholar
  11. 11.
    Cardiome Pharma Corp., Astellas Pharma US Inc. Cardiome And Astellas Announce Positive Results From Second Phase 3 Trial. Media Release: 29 Sep 2005. Available from URL: http://www.cardiome.com Google Scholar
  12. 12.
    Cardiome Pharma Corp, Astellas Pharma US Inc. Cardiome And Astellas Initiate ACT 4 Study. Media Release: 19 Oct 2005. Available from URL: http://www.cardiome.com Google Scholar
  13. 13.
    Cardiome Pharma Corp.. Cardiome Successfully Completes Second Phase 1 Trial. Media Release: 25 Apr 2005. Available from URL: http://www.cardiome.com Google Scholar
  14. 14.
    Cardiome Pharma Corp.. Cardiome Successfully Completes RSD1235 Oral Phase 1 Trial. Media Release: 31 Aug 2005. Available from URL: http://www.cardiome.com
  15. 15.
    Ezrin A, Grant S, Bell G, et al. Safety and pharmacokinetics of RSD1235, a novel atrial fibrillation converting drug, in healthy volunteers. Cardiovascular Drugs and Therapy 16 (Suppl. 1): 49, May 2002Google Scholar
  16. 16.
    Cardiome Pharma Corp. Cardiome Drug Effective for Heart Patients. Media Release: 3 Sep 2002. Available from URL: http://www.cardiome.com Google Scholar
  17. 17.
    Roy D, Beatch G, Steill I, et al. RSD1235 rapidly and effectively terminates atrial fibrillation. European Heart Journal 24 (Abstr. Suppl.): 720, Aug–Sep 2003CrossRefGoogle Scholar
  18. 18.
    Pratt C, Roy D, Juul-Møller S, et al. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a phase III, randomized, placebo-controlled, multicenter trial. Journal of the American College of Cardiology 47 (Suppl. A): 10 (plus oral presentation) abstr. 804-3, No. 4, 21 Feb 2006Google Scholar
  19. 19.
    Dorian P, Mangat I, Korley V, et al. Electrophysiological properties of an atrial selective antiarrhythmic agent, RSD1235, in humans. Circulation 110 (Suppl.): 461, No. 17, 26 Oct 2004Google Scholar
  20. 20.
    Dorian P, Mangat I, Korley V, et al. Electrophysiological properties of an atrial selective antiarrhythmic agent, RSD1235, in humans. Canadian Journal of Cardiology 20 (Suppl. D): 198, Oct 2004Google Scholar
  21. 21.
    Cardiome Pharma Corp. Cardiome Announces Positive Phase 2a Results For Oral RSD1235. Media Release: 13 Sep 2006. Available from URL: http://www.cardiome.com
  22. 22.
    Cardiome Pharma Corp. Cardiome Announces Interim Phase 2a Results for Oral RSD1235. Media Release: 24 Jul 2006. Available from URL: http://www.cardiome.com Google Scholar
  23. 23.
    Cardiome Pharma Corp, Fujisawa Healthcare Inc. Cardiome reports additional ACT 1 clinical results. Media Release: 4 Feb 2005. Available from URL: http://www.cardiome.com Google Scholar

Copyright information

© Adis Data Information BV 2007

Personalised recommendations